placebo to ramipril

DRUG3 trials

Sponsors

Novartis, Novartis Pharmaceuticals, Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

Conditions

Heart FailureHypertensionRenal Insufficiency, Chronic

Phase 2

Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure

CompletedNCT00923156

Novartis PharmaceuticalsHeart Failure

Start: 2009-05-31End: 2011-02-28Updated: 2012-07-26

Phase 3

Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome

CompletedNCT01485978

Institut fuer anwendungsorientierte Forschung und klinische Studien GmbHRenal Insufficiency, Chronic

Start: 2012-03-31End: 2019-03-31Updated: 2020-06-17

Phase 4

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

CompletedNCT00631917

NovartisHypertension

Start: 2008-02-29End: 2009-09-30Updated: 2011-07-12

Related Papers

Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport.

2025-04-0115 citations

Ratio of Urinary Proteins to Albumin Excretion Shifts Substantially during Progression of the Podocytopathy Alport Syndrome, and Spot Urine Is a Reliable Method to Detect These Pathologic Changes

Cells2023-05-077 citations

Challenges for academic investigator-initiated pediatric trials for rare diseases.

2014-02-015 citations

Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients.

2012-07-0150 citations